LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 220

Search options

  1. Article ; Online: Smartphone and video games overuse effects on hand joints: time for screening interventions?

    Megna, M / Gisonni, P / Balato, N

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2018  Volume 32, Issue 12, Page(s) e457–e458

    MeSH term(s) Behavior, Addictive ; Hand Joints ; Smartphone ; Ultrasonography ; Video Games
    Language English
    Publishing date 2018-05-27
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.15056
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Real-life effectiveness of biological drugs on psoriatic difficult-to-treat body regions: scalp, palmoplantar area and lower limbs.

    Megna, M / Cirillo, T / Balato, A / Balato, N / Gallo, L

    Journal of the European Academy of Dermatology and Venereology : JEADV

    2018  Volume 33, Issue 1, Page(s) e22–e23

    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological Products/therapeutic use ; Female ; Foot/pathology ; Hand/pathology ; Humans ; Leg/pathology ; Male ; Middle Aged ; Psoriasis/drug therapy ; Psoriasis/pathology ; Scalp/pathology ; Young Adult
    Chemical Substances Biological Products
    Language English
    Publishing date 2018-06-26
    Publishing country England
    Document type Letter
    ZDB-ID 1128828-0
    ISSN 1468-3083 ; 0926-9959
    ISSN (online) 1468-3083
    ISSN 0926-9959
    DOI 10.1111/jdv.15119
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Psoriasis in a cohort of patients with common variable immunodeficiency.

    Megna, M / Pecoraro, A / Balato, N / Villani, A / Crescenzi, L / Balato, A / Spadaro, G

    The British journal of dermatology

    2019  Volume 180, Issue 4, Page(s) 935–936

    MeSH term(s) Adult ; Common Variable Immunodeficiency/complications ; Common Variable Immunodeficiency/drug therapy ; Common Variable Immunodeficiency/immunology ; Female ; Humans ; Immunoglobulins, Intravenous/administration & dosage ; Male ; Middle Aged ; Prospective Studies ; Psoriasis/diagnosis ; Psoriasis/epidemiology ; Psoriasis/immunology
    Chemical Substances Immunoglobulins, Intravenous
    Language English
    Publishing date 2019-02-25
    Publishing country England
    Document type Letter ; Observational Study
    ZDB-ID 80076-4
    ISSN 1365-2133 ; 0007-0963
    ISSN (online) 1365-2133
    ISSN 0007-0963
    DOI 10.1111/bjd.17408
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: A Familial Novel Putative-Pathogenic Mutation Identified in Plaque-Psoriasis by a Multigene Panel Analysis.

    Nunziato, Marcella / Balato, Anna / Ruocco, Anna / D'Argenio, Valeria / Di Caprio, Roberta / Balato, Nicola / Ayala, Fabio / Salvatore, Francesco

    International journal of molecular sciences

    2023  Volume 24, Issue 5

    Abstract: Psoriasis is a chronic multifactorial skin disorder with an immune basis. It is characterized by patches of skin that are usually red, flaky and crusty, and that often release silvery scales. The patches appear predominantly on the elbows, knees, scalp ... ...

    Abstract Psoriasis is a chronic multifactorial skin disorder with an immune basis. It is characterized by patches of skin that are usually red, flaky and crusty, and that often release silvery scales. The patches appear predominantly on the elbows, knees, scalp and lower back, although they may also appear on other body areas and severity may be variable. The majority of patients (about 90%) present small patches known as "plaque psoriasis". The roles of environmental triggers such as stress, mechanical trauma and streptococcal infections are well described in psoriasis onset, but much effort is still needed to unravel the genetic component. The principal aim of this study was to use a next-generation sequencing technologies-based approach together with a 96 customized multigene panel in the attempt to determine if there are germline alterations that can explain the onset of the disease, and thus to find associations between genotypes and phenotypes. To this aim, we analyzed a family in which the mother showed mild psoriasis, and her 31-year-old daughter had suffered from psoriasis for several years, whereas an unaffected sister served as a negative control. We found variants already associated directly to psoriasis in the
    MeSH term(s) Adult ; Female ; Humans ; Genetic Predisposition to Disease ; Mutation ; Phenotype ; Psoriasis/etiology ; Psoriasis/genetics ; Streptococcal Infections/complications
    Chemical Substances TRAF3IP2 protein, human
    Language English
    Publishing date 2023-03-01
    Publishing country Switzerland
    Document type Case Reports
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms24054743
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Adult Atopic Dermatitis: Less Certainty, More Challenges.

    Megna, M / Patruno, C / Balato, A / Napolitano, M / Balato, N

    Journal of investigational allergology & clinical immunology

    2017  Volume 27, Issue 4, Page(s) 276–277

    MeSH term(s) Adult ; Dermatitis, Atopic ; Humans
    Language English
    Publishing date 2017
    Publishing country Spain
    Document type Journal Article
    ZDB-ID 1128657-x
    ISSN 1018-9068
    ISSN 1018-9068
    DOI 10.18176/jiaci.0155
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: A case of erythrodermic psoriasis successfully treated with ixekizumab.

    Megna, Matteo / Gallo, Lucia / Balato, Nicola / Balato, Anna

    Dermatologic therapy

    2019  Volume 32, Issue 2, Page(s) e12825

    Abstract: Erythrodermic psoriasis (EP) is the most severe form of psoriasis, resulting in significant morbidity and mortality. International guidelines on EP treatment are lacking, with most of the biologic drugs being used basing on case reports or small case ... ...

    Abstract Erythrodermic psoriasis (EP) is the most severe form of psoriasis, resulting in significant morbidity and mortality. International guidelines on EP treatment are lacking, with most of the biologic drugs being used basing on case reports or small case series. Ixekizumab, a fully human anti-interleukin (IL)-17A monoclonal antibody, is approved for moderate to severe plaque psoriasis while its use in EP is off label. However, two studies conducted on eight Japanese EP patients have showed ixekizumab as an efficacious and well tolerated therapy up to 24 and 52 weeks, respectively. To date, no case reports on Caucasian patients have been described. We report the case of a 66-year-old Caucasian female with EP successfully treated with ixekizumab, reaching PASI 100 after only 6 weeks of therapy and still maintaining this response at week 24. Our case report suggests ixekizumab as a highly efficacious treatment in EP, presenting also a very rapid action which leads to complete resolution of the disease after 6 weeks. Further studies are warrant to confirm our data, with controlled trials specifically dedicated to EP being strictly needed in order to verify the role and efficacy of the new biologics in EP.
    MeSH term(s) Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Dermatitis, Exfoliative/drug therapy ; Dermatitis, Exfoliative/pathology ; Dermatologic Agents/therapeutic use ; Female ; Humans ; Interleukin-17/immunology ; Psoriasis/drug therapy ; Psoriasis/pathology ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal, Humanized ; Dermatologic Agents ; IL17A protein, human ; Interleukin-17 ; ixekizumab (BTY153760O)
    Language English
    Publishing date 2019-01-31
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 1354801-3
    ISSN 1529-8019 ; 1396-0296
    ISSN (online) 1529-8019
    ISSN 1396-0296
    DOI 10.1111/dth.12825
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Rational ideation and empiric validation of an innovative digital dermographic tester.

    Lembo, C / Patruno, C / Balato, N / Ayala, F / Balato, A / Lembo, S

    Clinical and experimental dermatology

    2018  Volume 43, Issue 3, Page(s) 268–273

    Abstract: Background: Dermographism is a condition characterized by a weal response to a combination of pressure and traction on skin surface, and its diagnosis is based on medical history, clinical criteria and provocation test. The Dermographic Tester: Aim: ... ...

    Abstract Background: Dermographism is a condition characterized by a weal response to a combination of pressure and traction on skin surface, and its diagnosis is based on medical history, clinical criteria and provocation test. The Dermographic Tester
    Aim: To validate the effectiveness and accuracy of the DDT.
    Methods: We tested the DDT on 213 participants purposely sampled to obtain three groups, each with a different pattern of reaction to mechanical stimuli. Based on anamnestic, diagnostic and symptomatic criteria, patients were divided into dermographic urticaria (DU), spontaneous urticaria (SU) and healthy control (HC) groups. The DDT was used to apply 12 levels of pressure to the skin surface, and a frequency distribution of positive reactions was displayed for each group.
    Results: A force of 36-40 g/mm
    Conclusions: The DDT was found to be capable of differentiating patients with DU patients from those with SU and from HCs, and was able to precisely identify the weal elicitation threshold.
    MeSH term(s) Adolescent ; Adult ; Aged ; Child ; Female ; Humans ; Male ; Middle Aged ; Pressure/adverse effects ; Sensitivity and Specificity ; Skin/pathology ; Skin Tests/instrumentation ; Surveys and Questionnaires ; Urticaria/diagnosis ; Urticaria/etiology ; Young Adult
    Language English
    Publishing date 2018-04
    Publishing country England
    Document type Journal Article ; Validation Studies
    ZDB-ID 195504-4
    ISSN 1365-2230 ; 0307-6938
    ISSN (online) 1365-2230
    ISSN 0307-6938
    DOI 10.1111/ced.13314
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Letter to the editor submitted in response to "psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab".

    Megna, Matteo / Villani, Alessia / Balato, Nicola / Balato, Anna

    The Journal of dermatological treatment

    2018  Volume 30, Issue 3, Page(s) 309

    MeSH term(s) Dermatologic Agents ; Female ; Humans ; Pregnancy ; Psoriasis ; Ustekinumab
    Chemical Substances Dermatologic Agents ; Ustekinumab (FU77B4U5Z0)
    Language English
    Publishing date 2018-09-03
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.1080/09546634.2018.1508818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Psoriatic arthritis onset in psoriatic patients receiving UV phototherapy in Italy.

    Balato, Anna / Caiazzo, Giuseppina / Balato, Nicola / Napolitano, Maddalena

    Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia

    2018  Volume 155, Issue 6, Page(s) 733–738

    Abstract: Background: Psoriasis is a chronic, recurrent, and immune-mediated inflammatory disease that affects 2-3% of the world population. A substantial proportion of patients with psoriasis, approximately 40%, develop a form of inflammatory arthritis known as ... ...

    Abstract Background: Psoriasis is a chronic, recurrent, and immune-mediated inflammatory disease that affects 2-3% of the world population. A substantial proportion of patients with psoriasis, approximately 40%, develop a form of inflammatory arthritis known as psoriatic arthritis (PsA), the arthritis follows the development of psoriasis, and it will develop simultaneously or possibly before the appearance of skin lesions. The presence of PsA indicates a need for more active intervention rather than purely topical therapies or UV-based therapies. The aim of this multicenter, retrospective, epidemiological study was to estimate the incidence of PsA in psoriatic patients receiving UV treatment as monotherapy.
    Methods: A retrospective epidemiological study was performed in 8 dermatological reference center, located throughout Italy (2 from Northern, 3 from Center, 3 from Southern); a period of 1 year was considered. Data from the overall study population including 326 patients with a diagnosis of psoriasis were analyzed. Furthermore, data coming from follow-up visits, including screening for PsA onset through specific questionnaires were analyzed.
    Results: PsA screening was positive in 27 patients (8.3%), whereas PsA diagnosis was confirmed by a rheumatologist in only 22/27 (81.5%) being therefore found in 22/326 (6.7%). Patients diagnosed with PsA had a statistically significantly higher abdominal circumference (96±15.3 vs. 88.9±18.3, P=0.048) and more commonly presented a positive past medical history for phototherapy (90.9% vs. 57.6% P=0.004).
    Conclusions: Our study showed that phototherapy is not able to prevent or slow down the risk of PsA development in psoriatic patients. PsA screening should be always carried out in those patients even if asymptomatic, especially in obese subjects which are at great risk to develop PsA due to their increased systemic inflammatory state.
    MeSH term(s) Adipose Tissue/metabolism ; Adult ; Alcohol Drinking/epidemiology ; Anti-Inflammatory Agents/therapeutic use ; Arthritis, Psoriatic/diagnosis ; Arthritis, Psoriatic/epidemiology ; Arthritis, Psoriatic/etiology ; Cardiovascular Diseases/epidemiology ; Comorbidity ; Cytokines/metabolism ; Female ; Humans ; Immunosuppressive Agents/therapeutic use ; Male ; Metabolic Syndrome/epidemiology ; Middle Aged ; Obesity/complications ; Psoriasis/drug therapy ; Psoriasis/radiotherapy ; Risk Factors ; Smoking/epidemiology ; Ultraviolet Therapy ; Waist Circumference
    Chemical Substances Anti-Inflammatory Agents ; Cytokines ; Immunosuppressive Agents
    Language English
    Publishing date 2018-09-24
    Publishing country Italy
    Document type Journal Article ; Multicenter Study
    ZDB-ID 604114-0
    ISSN 1827-1820 ; 0026-4741 ; 0392-0488
    ISSN (online) 1827-1820
    ISSN 0026-4741 ; 0392-0488
    DOI 10.23736/S0392-0488.18.06117-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Guselkumab for the treatment of psoriasis.

    Megna, Matteo / Balato, Anna / Raimondo, Annunziata / Balato, Nicola

    Expert opinion on biological therapy

    2018  Volume 18, Issue 4, Page(s) 459–468

    Abstract: Introduction: Psoriasis is a chronic immune mediated disease in which the interplay of T cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 axis is currently considered to be crucial in the pathogenesis of ... ...

    Abstract Introduction: Psoriasis is a chronic immune mediated disease in which the interplay of T cells and keratinocytes seems to play a key role. In this context, the interleukin (IL)-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis and the selective inhibition of IL-23 may be viewed as an improvement of treatments blocking both IL-23 and IL-12, since its upstream actions. Areas covered: The authors performed a thorough and updated review on guselkumab, a fully human IgG1λ monoclonal antibody that blocks the p19 subunit of IL-23, analyzing efficacy and safety data from phase I, II and III trials. Expert opinion: Guselkumab represents a very promising therapy, providing an alternative mechanism of action with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/23. Guselkumab will definitively shift therapeutic goals of psoriasis management from PASI 75 to PASI 90 and 100 due to its exciting trials results, also favored by its increased treatment adherence due to its administering regimen (100 mg injection at week 0, 4 and then every 8 weeks).
    MeSH term(s) Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/chemistry ; Antibodies, Monoclonal/pharmacokinetics ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials as Topic ; Half-Life ; Humans ; Interleukin-23/immunology ; Interleukin-23/metabolism ; Nasopharyngitis/etiology ; Psoriasis/drug therapy ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Interleukin-23 ; guselkumab (089658A12D)
    Language English
    Publishing date 2018-03-03
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2052501-1
    ISSN 1744-7682 ; 1471-2598
    ISSN (online) 1744-7682
    ISSN 1471-2598
    DOI 10.1080/14712598.2018.1445223
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top